Victor Moreno
General Practice · Maunabo, PRNPI 1467568725
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Merck accounts for 66.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for general practice clinicians in PR, where the typical reported total is $178.
Across 2 payments — averaging $52.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$70
- E.r. Squibb & Sons, L.L.C.$35
Across 30 payments — averaging $30,101 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$503K
- Regeneron$236K
- Pfizer$146K
- Genmab A/s$10K
- E.r. Squibb & Sons, L.L.C.$3K
- GSK$3K
- plus $2K from 1 others
What the payments were for
- Food & beverage$105100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $70 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
How this compares
$105 in reported general payments places this provider in the 35th percentile of 3,586 general practice providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 39 | $36,434 |
| XareltoRivaroxaban | 25 | $28,630 |
| EliquisApixaban | 21 | $15,792 |
| JanuviaSitagliptin Phosphate | 22 | $15,148 |
| Omega-3 Acid Ethyl Esters | 190 | $12,856 |
| SynthroidLevothyroxine Sodium | 119 | $12,494 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $12,066 |
| JentaduetoLinagliptin/Metformin Hcl | 11 | $9,761 |
| LantusInsulin Glargine,hum.Rec.Anlog | 44 | $6,661 |
| Levothyroxine Sodium | 234 | $4,298 |
| Simvastatin | 381 | $3,972 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 147 | $3,725 |
| Atorvastatin Calcium | 236 | $3,270 |
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 44 | $3,059 |
| Clonazepam | 126 | $2,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $70 | $27,21334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in Maunabo
- Wilfredo CuevasSan Lorenzo$530K
- Julio BacoMayaguez$268K
- Soria Diaz BaezPonce$192K
- Carlos RomanCanovanas$140K
- William E TorresSan Juan$86K
- Rafael Mendoza RodriguezPonce$77K
- Frank Perez NogueiraSan German$70K
- Vivian Tamayo AgraitSan Juan$64K
- William Soto AvilesToa Baja$63K
- Jessica RosarioSanturce$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.